OverviewChartNewsTraderScreen

Soc. Generale Knock-Out AYJ/  DE000SU15AA3  /

Frankfurt Zert./SG
09/10/2024  16:34:00 Chg.+0.040 Bid17:30:03 Ask- Underlying Strike price Expiration date Option type
4.540EUR +0.89% -
Bid Size: -		 -
Ask Size: -		 VALNEVA SE EO... 7.1428 EUR 31/12/2078 Put
GlobeNewswire 03/09 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
GlobeNewswire 13/08 Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 01/08 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’...
GlobeNewswire 22/07 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the Wo...
GlobeNewswire 17/07 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
GlobeNewswire 01/07 Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ...
GlobeNewswire 26/06 Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Direct...
GlobeNewswire 24/06 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
GlobeNewswire 05/06 Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...
GlobeNewswire 04/06 Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
GlobeNewswire 03/06 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 31/05 Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
GlobeNewswire 21/05 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GlobeNewswire 13/05 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire 07/05 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 26/03 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GlobeNewswire 25/03 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire 21/03 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire 20/03 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 18/03 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire 04/03 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire 29/02 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire 15/02 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 05/02 Valneva Announces Sale of Priority Review Voucher for $103 Million
GlobeNewswire 10/01 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine